City page
Aarhus biotech and pharma directory
This page shows why the city matters, which categories are strongest there, and which compliance or quality markers are already visible in public evidence.
Where does this city read strongest?
Therapeutics (2) and Biotech (1). Most visible records: Commit Biologics ApS, NMD Pharma A/S, and STipe Therapeutics ApS.
Which standards and public evidence are already visible?
Not yet available.. Latest review: 24 April 2026. Review cycle: April 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Aarhus.
By category
Aarhus by category
Jump into a category page filtered to this country only.
Full list
Aarhus biotech and pharma directory
3 city records currently match the active filter.
Current review cycle
Commit Biologics ApS
AarhusDenmarkBiotech
Aarhus preclinical biotech building complement-powered immune-engager biologics through the BiCE Complement Engager platform, with a 2025 non-human primate proof-of-concept milestone and a newly named CEO from March 2026.
- Lead
- Thomas L. F. Montgomery AndresenChief Executive Officer
- Scale
- Preclinical biotech development
Current review cycle
NMD Pharma A/S
AarhusDenmarkTherapeutics
Aarhus clinical-stage neuromuscular biotech developing ClC-1 chloride-channel inhibitors to restore muscle function, with lead candidate NMD670 in Phase 2 for myasthenia gravis.
- Lead
- Thomas Holm PedersenCo-Founder and Chief Executive Officer
- Scale
- Clinical-stage small-molecule development
Current review cycle
STipe Therapeutics ApS
AarhusDenmarkTherapeutics
Aarhus preclinical immuno-oncology biotech developing STING-pathway priming small molecules to convert cold tumors into immune-responsive ones, with a 20 million EUR Series A financing completed in 2019.
- Lead
- Claus Elsborg OlesenCo-Founder and Chief Executive Officer
- Scale
- Preclinical small-molecule development
Related briefs
Briefs that mention Aarhus
Nordic Biotech Landscape 2026: Denmark, Sweden, Finland, Norway
A practical map of the Nordic biotech and pharma landscape in 2026 — 124 operators across Denmark, Sweden, Finland, and Norway, anchored by Novo Nordisk, Genmab, Lundbeck, AstraZeneca Gothenburg, Bavarian Nordic, Orion, and a dense Medicon Valley + Karolinska cluster layer.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.